Key Quantitative Figures

  • Final dividend declared: ₹5.00 per equity share for financial year 2025-26
  • Consolidated revenue: ₹582 billion (11.9% growth)
  • EBITDA: ₹177 billion (16.1% growth)
  • Adjusted net profit: ₹124 billion
  • Net worth: ₹836 billion
  • R&D expenditure: ₹35.5 billion (6.1% of sales)
  • India revenues: ₹193 billion (14% growth, 8.4% market share)
  • US revenues: ₹168 billion (29% of consolidated sales)
  • Emerging Markets revenues: ₹112 billion (18.8% growth)
  • Rest of World revenues: ₹86 billion (19.6% growth)
  • Renewable energy consumption: 52.6%
  • Greenhouse gas emissions reduction: 16.7% from baseline

Dates and Timeline

  • AGM date: 31 July 2026
  • Meeting duration: 4:00 PM to 5:50 PM IST
  • Remote e-voting period: 27 July 2026 to 30 July 2026
  • Dr. Andreas Busch's term: 12 May 2026 to 11 May 2031
  • Mr. Aalok Shanghvi's tenure: up to 31 May 2028

Parties Involved

  • Cost Auditors: M/s. Narasimha Murthy & Co.
  • Scrutinizer: Mr. Chintan Goswami, Partner of KJB & CO LLP
  • Acquisition target: Organon & Co.
  • Key personnel: Mr. Dilip Shanghvi (Executive Chairman), Mr. Kirti Ganorkar (Managing Director), Mr. Anoop Deshpande (Company Secretary and Compliance Officer)

Resolutions Approved

Ordinary Business:

  • Adoption of Audited Standalone Financial Statements for FY26
  • Adoption of Audited Consolidated Financial Statements for FY26
  • Re-appointment of Mr. Aalok Shanghvi (DIN: 01951829) as Director
  • Declaration of Final Dividend of ₹5.00 per equity share
  • Payment of commission to Independent Directors within statutory limits
  • Appointment of Dr. Andreas Busch (DIN: 11699735) as Independent Director for 5 years

Special Business:

  • Ratification of remuneration of M/s. Narasimha Murthy & Co., Cost Accountants for FY26-27
  • Revision in remuneration of Mr. Aalok Shanghvi for remaining tenure up to 31 May 2028

Business Performance Highlights

Innovative Medicines:

  • Contributed 22% of consolidated sales
  • Surpassed US generics business in revenue contribution for first time
  • 29 innovative medicines marketed globally
  • Launched LEQSELVI™ for severe alopecia areata and UNLOXCYT™ for advanced cutaneous squamous cell carcinoma in US

India Business:

  • Maintained position as India's largest pharmaceutical company
  • Launched ILUMYA® in India
  • Entered GLP-1 segment with Noveltreat and Sematrinity for diabetes and weight management

Strategic Development:

  • Proposed acquisition of Organon & Co. (largest transaction in company history)
  • Acquisition expands into Women's Health, strengthens Established Brands, and provides biosimilars entry

Operational Metrics

  • R&D organization: 2,700+ scientists across six global R&D centers
  • Total employees: 47,000+
  • CSR impact: 1+ million lives positively impacted